Jason Lettmann
2023
In 2023, Jason Lettmann earned a total compensation of $4.9M as Chief Executive Officer at ALX ONCOLOGY HOLDINGS.
Compensation breakdown
| Non-Equity Incentive Plan | $119,003 |
|---|---|
| Option Awards | $4,369,560 |
| Salary | $217,330 |
| Other | $151,290 |
| Total | $4,857,183 |
Lettmann received $4.4M in option awards, accounting for 90% of the total pay in 2023.
Lettmann also received $119K in non-equity incentive plan, $217.3K in salary and $151.3K in other compensation.
Rankings
In 2023, Jason Lettmann's compensation ranked 118th out of 2,311 executives tracked by ExecPay. In other words, Lettmann earned more than 94.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 118 out of 2,311 | 95th |
Division Manufacturing | 63 out of 1,247 | 95th |
Major group Chemicals And Allied Products | 39 out of 705 | 95th |
Industry group Drugs | 38 out of 676 | 94th |
Industry Pharmaceutical Preparations | 26 out of 490 | 95th |
Source: SEC filing on April 22, 2024.
Lettmann's colleagues
We found three more compensation records of executives who worked with Jason Lettmann at ALX ONCOLOGY HOLDINGS in 2023.